We have examined the prothrombin gene äs a candidate gene for venous thrombosis in selected patients with a documented familial history of venous thrombophilia All the exons and the 5'-and 3'-UT region of the prothrombin gene were analyzed by polymerase chain reaction and direct sequencing in 28 probands Except for known polymorphic sites, no deviations were found in the coding regions and the 5'-UT region. Only one nucleotide change (a G to A transition) at position 20210 was identified in the sequence of the 3'-UT region Eighteen percent of the patients had the 20210 AG genotype, äs compared with 1% of a group of healthy controls (100 subjects) In a population-based case-
D EEP-VEIN THROMBOSIS is a common disease, with
an annual mcidence in the general population of ap proximately l per l ,000 ' Risk factors include both hereditary and acquired conditions ^ Generally, a tendency toward venous thrombosis could anse from hyperactive coagulation pathways, hypoactive anticoagulant mechamsms, or hypoactive fibnnolysis " Mutations in genes that encode protems in these pathways play an important role in the predisposition to venous thrombosis Λ Vanant alleles of the genes encoding protein C, 1 protein S, 46 antithrombin, 7 and fibnnogen 8 have been shown to be relatively strong, but uncommon nsk factors for thrombosis 9 Genetic analysis of these genes showed a large heterogeneity of mutations ' 8 More recently, a poor anticoagulant response of plasma to activated protein C (APC) 10 " due to the presence of a mutant factor V molecule 1 -(factor V Leiden) was discovered and is äs yet the most common hereditary nsk factor foi thrombosis known Recently, some support was obtamed for the hypothesis that the clustenng ot thrombosis in famihes is due to epistatic effects 2 Studies in selected famihes with venous thrombosis indicated that the piesence of mutations in two genes may increase the penetrance of the thrombotic disease π T he discovery of genetic nsk factors tor thrombosis came after the identincation ot famihes in whom the thrombophilia segregated with an abnormal result in a plasma lest (protein C, protein S, antithrombin, and APC resistance) '"""' 2I However, despite the ever growing insight mto the processes of coagulation and hbrinolysis, the underlymg cause of many control study, the 20210 A allele was identified äs a common allele (allele frequency, 1 2%; 95% confidence interval, 0.5% to 1.8%), which increased the risk of venous thrombosis almost threefold (odds ratio, 2 8; 95% confidence interval, 1.4 to 5.6) The risk of thrombosis increased for all ages and both sexes An association was found between the presence of the 20210 A allele and elevated prothrombin levels. Most individuals (87%) with the 20210 A allele are in the highest quartile of plasma prothrombin levels (>1.15 U/mL). Elevated prothrombin itself also was found to be a risk factor for venous thrombosis © 7996 by The American Society of Hematology inhented thrombotic events remains unsolved New technologies for genetic analysis of thrombophilic famihes offer the opportunity to use a direct genetic strategy for Identification of other genetic defects involved in inheritable thrombophi-
ha --We investigated the prothrombin gene äs a candidate gene for venous thrombosis Prothrombin is the precursor of the senne protease thrombin, a key enzyme m the processes of hemostasis and thrombosis, that exhibits procoagulant, anticoagulant, and antifibnnolytic activities 21 " Prothrombin is encoded by a 21 -kb-long gene 26 locahzed on chromosome L l, posifon 11 p 11 -q 12 27 The prothrombin gene is organized in 14 exons, separated by 13 introns with the 5' upstream untranslated (UT) region and the 3' UT region, 2 · 6 which may play regulatory loles in gene expression
The aim of the present study was to perform an analysis of the prothrombin genes of selected subjects with a history of venous thrombophilia usmg polymerase chain reaction (PCR) and direct sequencmg of the coding regions and their flanking sphce junctions and the 5'-and 3'-UT regions One genetic Variation in the 3'-UT region of the prothrombin gene, a G to A transition at nucleotide position 20210, was found in 18% of selected patients with a personal and family history of venous thrombosis, m 6 2% of unselected consecutive patients with a first, objectively confirmed episode of deep-vem thrombosis, and in 2 3% of healthy control subjects Camers of the 20210 A allele have higher plasma prothrombin levels than controls with the normal 20210 GG genotype and have a 2 8-fold increased risk of venous thrombosis
MATERIALS AND METHODS

Subjetts
In a previous study, we collected detailed Information on the occurrence of venous thrombo embohc events m the famihes of l Π probands with a personal and family history of venous thrombophilia IK From these, we randomly selected 28 famihes usmg the following cntena (1) apart from the probapd, there should be at least two symptomatic (pieferentially first degree) relatives, and (2) m probands and symptomatic relatives, deficiencies of protein C, protein S, antithrombin, or plasmmogen or dysfibnnogenemia were excluded On average, each proband had 2 4 (ränge, l to 6) symp tomatic first degree relatives and l 8 (ränge, 0 to 5) symptomatic second degree relatives All probands and fatruly members gave their mformed consent for the study of unexplamed famihal thrombophiha It was recently estabhshed by DNA analysis that, m this panel of probands, the frequency of the factor V Leiden mutation, 12 which is associated with a poor anticoagulant response to APC, 10 is 40%
The second group of patients came from a population-based case control study on venous thrombosis, the Leiden Thrombophiha Study (LETS) " Bnefly, patients were selected from the Computer files of the Anticoagulation Clmics m Leiden, Amsterdam, and Rot terdam In the Netherlands, Anticoagulation Clmics momtor couma rm treatment m virtually all patients with venous thrombosis m a deflned geographic area 29 30 Included are 474 unselected and consecutive outpatients younger than 70 years of age who were referred for anticoagulant treatment because of a first, objectively diagnosed episode of deep vem thrombosis The median time between the occurrence of the deep-vem thrombosis and blood collection was 19 months (ränge, 6 to 68 months) Nmety-one percent of the ehgible patients were willmg to take part m the study The thrombotic pa tients were asked to find their own healthy control subject accordmg to predefined cntena '' This resulted m 474 population control subjects matched for age and sex The mean age for patients and controls was 47 years (ränge, 16 to 70 years for patients, ränge, 16 to 73 years for controls) and the male/female ratio among patients and controls ahke was 3/4 ''
Blood collection and labomtory analysis Blood was collected m tubes contammg 0 106 mmol/L tnsodium citrate Plasmas were prepared by centnfugation for 10 minutes at 2,000g at room temperature and stored at -70°C m l 5 mL ahquots High molecular weight DNA was extracted from the white blood cell fraction usmg Standard methods Prothrombin activity was measured with a chromogemc method usmg S-2238 äs Substrate and Echis cannatus venom äs activator 31 Prothrombin antigen was determmed usmg a Laurell electroimmunoassay 31 Protein C activity was measured with Coamate protem C (Chromogemx, Molndal, Sweden) An amidolytic hepann cofactor assay (Chromogemx) was used for antithrombm activity measurements Total protem S antigen was determmed by polyclonal en zyme linked immunosorbent assay (ELISA) 32 The results are ex pressed m units per mühliter, in which l U refers to the activity or antigen present m l mL of pooled normal plasma
For the Identification of a geneüc abnormahty (or abnormahties) in the prothrombm gene in DNA from 28 probands with a family history of deep venous thrombosis, we used the PCR followed by direct sequencing 33 We compared these sequences with those of 5 healthy control mdividuals Genomic DNA was specifically amphfied for the 14 exons with their flanking regions and for the 5'-and 3' UT regions of the prothrombm gene usmg PCR 34 The pnmers used m the PCR were denved from the sequence of the gene 26 and are identical to those used m a previous study 33 The fragments obtamed by PCR were punfied on 1% ultralow meltmg temperature agarose gel The segment of the gel contammg the amphfied fragment was excised and sequenced with the appropnate pnmers usmg the dideoxynucleotide chain termmation method 35 Sequencing reactions were electrophoresed on 40-cm-long 8% polyacrylamide gels The gels were dned on Whatman 3 mm paper (Whatman, Maidstone, UK) and exposed to an χ ray film Genetic abnormahties identified by sequencing were confirmed by restnction enzyme digestion of amplified gene fragments When the abnormahty did not create or abohsh a restnction site, such a site was created by introducmg a nucleotide Substitution with a mutant ohgonucleotide dunng amplification 36 The mutant ohgonucleotide was designed with a nucleo tide Substitution close to the 3' end, such that the combmation of the nucleotide Substitution and the genetic abnormahty created a new restnction enzyme cleavage site Sequence vanations m the prothrombm gene known äs neutral polymorphic sites were identified on the basis of previous pubhshed data, 26 37 but are beyond the scope of this study Genetic analysis of the FV Leiden mutation (1691 G -> A) was performed äs previously descnbed
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Statistical analysis Odds ratios (ORs) were calculated äs a mea sure of relative nsk in the Standard unmatched fashion A 95% confidence interval (CI) was constructed accordmg to Woolf 3S Generally, the OR estimates the nsk of thrombosis when a nsk factor is present relative to the reference category For nsk factor analysis concerning plasma prothrombm values, 48 patients usmg oral anticoagulant therapy were excluded from the LETS group To assess a dose response relation, we stratified the prothrombm values of both patients and controls mto quartlies and calculated the ORs for the three higher levels relative to the lowest reference level Adjustment for current oral contraceptive use (yes/ no), body mass mdex (m kilograms per square meter), menopause (yes/no), smokmg (yes/no), age, and sex was performed by uncondi tional logistic regression Effect modification was assessed by strat ified analysis and logistic regression with interaction terms Materials Deoxynucleotides, dideoxynucleotides, and bovine serum albumm were purchased from Pharmacia (Uppsala, Sweden) (<* was found m DNA of 5 of the 28 probands (18%), but not in DNA of the 5 healthy control mdividuals (Fig 1) The presence of this sequence vanation was confirmed with restnction enzyme analysis usmg one mutagenic pnmer (Fig  2) In an extended analysis of 100 healthy subjects, the heterozygous state (20210 AG) was detected in 1% Homozygous (20210 A A) camers were absent Figure 3 shows the pedigree of the family of one of the five thrombophilic patients carrymg the vanant prothrombm allele Both the parents of the proband are heterozygous for the 20210 A allele, whereas her sister is homozygous Interestmgly, both the vanant prothrombm allele and the factor V Leiden allele segregate in this pedigree All mdividuals that expenenced a thrombotic event (or events) (II, l, III, l; III, 2) carry both genetic defects, whereas all carriers of a single defect are still Symptom free.
The high frequency (18%) of the 20210 A allele among patients with thrombophilia is probably affected by selection. To study the relevance of the 20210 A allele in the population, we undertook the analysis of a population-based patient-control study (LETS)."
The prevalence of carriers of the 20210 A allele among healthy control subjects in the LETS was 2.3%, which corresponds to an allele frequency of 1.2% (95% CI, 0.5% to 1.8%). Table l shows a higher prevalence of the 20210 AG genotype among patients (6.2%) than among control subjects (2.3%). Homozygous AA carriers were not found (expected prevalence, 0.014%). The relative risk for thrombosis associated with the 20210 A allele was 2.8 (95% CI, 1.4 to 5.6). This association persisted when controlling for age, sex, current pill use, body mass index, menopause, and smoking. The 20210 A allele was associated with an increased risk for thrombosis both in men and women. We also found that the 20210 A allele increased the risk for all age groups.
The increased risk (2.8) associated with the 20210 A allele was not the result of overrepresentation of other risk factors, such äs APC resistance (factor V Leiden); a deficiency of protein C, protein S, or antithrombin; or the presence of lupus anticoagulants. After excluding all these subjects (n = 141), we found an unmatched OR for thrombosis of 2.7 (95% CI, 1.3 to5.6).
Individuais with the normal 20210 GG genotype had a mean prothrombin level of 1.05 U/mL (n = 860; SD, 0.15; ränge, 0.55 to 1.56), whereas individuals with the 20210 AG genotype had a significantly higher mean prothrombin level of 1.32 U/mL (n = 40; SD, 0.18; ränge, 0.95 to 1.78; P < .001). There was no notable difference in prothrombin levels between patients and control subjects within each of the two genotypic groups. The mean levels (in units per milliliter) of protein C, total protein S, and antithrombin did not differ between the 20210 GG and 20210 AG genotype (1.03, 1.04, and 0.99 v 1.02, 1.03, and 0.98, respectively).
To assess to what extent an increased prothrombin level in itself is a risk factor for venous thrombosis, we stratified the prothrombin levels of patients and control subjects into quartiles ( Table 2 ). The OR increased with increasing prothrombin levels: subjects with a prothrombin level of greater than 1.15 U/mL had a 2.1-fold higher risk than those in the reference category (<0.95 U/mL). The high-risk stratum of greater than 1.15 U prothrombin/mL comprised no less than 31% of the patients and 20% of the control subjects. Table 3 over the different categories of prothrombin activity. Both in patients and control subjects, around 87% of the individuals with the 20210 AG genotype were in the highest category of prothrombin activity (>1.15 U/mL), whereas less notable differences were observed in individuals with the normal 20210 GG genotype.
DISCUSSION
Our study shows that a novel sequence Variation in the prothrombin gene (nt 20210 G->A) is a moderate risk factor for venous thrombosis (OR, 2.8; 95% CI, 1.4 to 5.6). The further observations that the 20210 A allele is associated with elevated prothrombin levels, that carriers of this allele have significantly higher prothrombin levels than noncarriers, and that elevated plasma prothrombin itself is also a risk factor for thrombosis suggest that the 20210 A allele acts through the elevated prothrombin levels.
In the LETS, the 20210 A allele was found in 6.3% of consecutive unselected patients with a first episode of deep vein thrombosis, indicating that the 20210 A allele is a relatively common risk factor for venous thrombosis. As expected, a much higher prevalence of 20210 A carriers was found in a group of selected patients with familial venous thrombosis (18%). In 60% of the 20210 A carriers, the 20210 A allele was the only genetic abnormality found, whereas in 40%, the FV Leiden mutation (R506Q) 12 was also present. The prevalence of carriers of the 20210 A allele among Values are the number of individuals with percentages in parentheses.
* Patients on oral anticoagulant treatment are excluded (n = 48).
controls was about 2.3%, corresponding to an allele frequency of 1.2% (95% CI, 0.5% to 1.8%). This is about eightfold higher than for protein C deficiency (0.3%)
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· 40 but about twofold less frequent than the so far most common genetic risk factor for venous thrombosis, the factor V Leiden mutation, which is associated with APC resistance (3% to 5%). 9 '" The 20210 A allele was not only found to be a risk factor for thrombosis but also to be associated with elevated prothrombin levels. Interestingly, elevated prothrombin levels were also a risk factor for thrombosis (Table 2 ). Thus, the prothrombin level may be considered äs an effector, suggesting also that other factors than the 20210 A allele can be responsible for high prothrombin levels. How elevated prothrombin levels may stimulate the formation of venous thrombi is still unclear. They may lead to an imbalance between the procoagulant, anticoagulant, and fibrinolytic System. For instance, when higher concentrations of prothrombin would lead to increased rates of thrombin generation, this might result in excessive growth of fibrin clots.
This study does not show the mechanism(s) by which the 20210 A allele of the prothrombin gene may contribute to higher prothrombin levels. The association found for these two variables (Table 3 ) and the location of 20210 G to A transition in the 3'-UT region of the prothrombin gene may indicate a relatively higher translation efficiency or higher stability of the transcribed mRNA. The G/A sequence Variation is located at the last position of the 3'-UT 26 at or near the cleavage site in the mRNA precursor to which poly A is added. Three conserved sequences in mRNA precursors, located in the vicinity of this site, are required for cleavage and polyadenylation: the AAUAAA sequence, the nucleotide to which poly A is added, and the region downstream of this nucleotide.
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· 42 Generally, the nucleotide to which poly A is added is an A, 41 ' 43 ' 44 mostly preceded by a C. 41 As a consequence of the G to A transition at position 20210, a CA dinucleotide (instead of GA) has been introduced at or near the cleavage and polyadenylation site. However, in vitro experiments so far do not support a hypothesis in which this nucleotide Substitution will result in an increased efficiency of the 3' end formation. 41 Alternatively, it cannot be excluded that the 20210 A allele is in linkage disequilibrium with another sequence Variation (that escaped our analysis) that is responsible for the elevated prothrombin levels. Finally, our approach of sequencing a candidate gene for thrombosis in a panel of probands from families with documented thrombophilia, followed by estimating the risk associated with any observed sequence Variation in a population based patient-control study, proved to be useful. This approach seems suitable for unraveling more unknown genetic defects in other candidate genes for inherited thrombophilia.
